In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our ...

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as ...

There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (FOP) on the US market, but ...

UK-based electronRx will launch a digital health technology (DHT) to help patients with respiratory disease manage their ...

Novo Nordisk is also ahead in the race to bring an oral GLP-1 to market for weight loss, as it has already filed semaglutide for FDA approval, with a decision before the end of this year, while Lilly ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

The importance of AI in pharma and life sciences cannot be overstated. Regardless of the aspect of industry you examine, ...